Bicara Therapeutics

(NASDAQ) BCAX

Current Price$21.69

Market Cap$1.42B

Since IPO (2024)-7%

5 YearN/A

1 Year+47%

1 Month+6%

Bicara Therapeutics Financials at a Glance

Market Cap

$1.42B

Revenue (TTM)

$0.00

Net Income (TTM)

$137.95M

EPS (TTM)

$-2.52

P/E Ratio

-8.59

Dividend

$0.00

Beta (Volatility)

1.73 (High)

Dividend

$0.00

Beta (Volatility)

1.73 (High)

Price

$21.69

Volume

297,745

Open

$21.60

Price

$21.69

Volume

297,745

Open

$21.60

Previous Close

$21.67

Daily Range

$21.37 - $22.46

52-Week Range

$7.80 - $24.25

Dividend

$0.00

Beta (Volatility)

1.73 (High)

Price

$21.69

Volume

297,745

Open

$21.60

Previous Close

$21.67

Daily Range

$21.37 - $22.46

52-Week Range

$7.80 - $24.25

BCAX News

Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?

Robert IzquierdoMar 30, 2026

Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.

Seena HassounaMar 26, 2026

BCAX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bicara Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

103

CEO

Claire Mazumdar, PhD, MBA

Website

www.bicara.com

Headquarters

Boston, MA 02116, US

BCAX Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-31%

Return on Capital

-39%

Return on Assets

-32%

Earnings Yield

-11.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.42B

Shares Outstanding

65.47M

Volume

297.75K

Avg. Volume

545.40K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$155.60M

EBITDA

$155.60M

Operating Cash Flow

$106.83M

Capital Expenditure

$280.00K

Free Cash Flow

$107.11M

Cash & ST Invst.

$414.80M

Total Debt

$1.71M

Bicara Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.42B

N/A

Market Cap/Employee

$25.79M

N/A

Employees

N/A

Net Income

$37.39M

-78.4%

EBITDA

$41.12M

-54.5%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$413.09M

-15.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$593.00K

+352.7%

Short Term Debt

$1.12M

+84.0%

Return on Assets

-32.01%

N/A

Return on Invested Capital

-38.70%

N/A

Free Cash Flow

$24.12M

+19.8%

Operating Cash Flow

$23.89M

+20.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

FTREFortrea Holdings Inc.

FTREFortrea Holdings Inc.$12.18+5.91%

EYPTEyePoint Pharmaceuticals, Inc.

EYPTEyePoint Pharmaceuticals, Inc.$13.34+1.06%

SEPNSepterna, Inc.

SEPNSepterna, Inc.$23.61-0.63%

SVRASavara Inc.

SVRASavara Inc.$5.12-2.29%

MRVIMaravai LifeSciences Holdings, Inc.

MRVIMaravai LifeSciences Holdings, Inc.$3.73+1.36%

PHATPhathom Pharmaceuticals, Inc.

PHATPhathom Pharmaceuticals, Inc.$12.01+7.23%

KURAKura Oncology, Inc.

KURAKura Oncology, Inc.$8.77-0.74%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$99.62+0.05%

NOKNokia

NOKNokia$13.30+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.07+0.05%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.70+0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.43+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$65.30+0.03%

TSLATesla

TSLATesla$390.82+0.02%

Questions About BCAX

What is the current price of Bicara Therapeutics?

Bicara Therapeutics is trading at $21.67 per share.

What is the 52-week range for Bicara Therapeutics?

Over the past 52 weeks, Bicara Therapeutics has traded between $7.80 and $24.25.

How much debt does Bicara Therapeutics have?

As of the most recent reporting period, Bicara Therapeutics reported total debt of $1.71M.

How much cash does Bicara Therapeutics have on hand?

Bicara Therapeutics reported $96.69M in cash and cash equivalents in its most recent financial results.

What is Bicara Therapeutics’s dividend yield?

Bicara Therapeutics does not currently have a dividend yield.

Bicara Therapeutics

Bicara Therapeutics Financials at a Glance

BCAX News

Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?

Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.

BCAX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Bicara Therapeutics

BCAX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Bicara Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BCAX

What is the current price of Bicara Therapeutics?

What is the 52-week range for Bicara Therapeutics?

How much debt does Bicara Therapeutics have?

How much cash does Bicara Therapeutics have on hand?

What is Bicara Therapeutics’s dividend yield?

Premium Investing Services